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Individuals with elevated depressive symptoms and substance use disorders (SUDs) 
have particular difficulties quitting smoking and few treatments benefit these 
individuals. The current study compared five session BA-enhanced smoking cessation 
treatment + nicotine replacement therapy (BADAS) to smoking cessation treatment as 
usual (TAU; nicotine replacement therapy + Clearing the Air self-help manual). We 
hypothesized that participants in BADAS would be less likely to relapse, would have 
higher abstinence rates, would smoke fewer cigarettes, would exhibit decreases in 
depressive symptoms, and would have increases in environmental reward, as 
compared to TAU. Participants in residential treatment with elevated depressive 
symptoms and SUDs and were randomized to BADAS or to TAU. Participants in 
BADAS were significantly less likely to relapse during the first week post-quit; 
  
abstinence and cigarette consumption rates did not differ significantly across 
treatments. All participants displayed reductions in depressive symptoms and 
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Chapter 1: Introduction 
Overview. 
Tobacco use constitutes the leading, non-infectious cause of death and disease 
worldwide and half of the people who currently smoke will eventually die from 
smoking related causes (Center for Disease Control and Prevention, 2011; World 
Health Organization, 2007). In the United States, 20% of total deaths are related to 
smoking, accounting for 438,000 annual deaths, which is more than the number of 
deaths caused by motor vehicle injuries, suicides, HIV, drugs, alcohol, and murder 
combined (CDC, 2008; 2011). Tobacco use has an enormous financial cost, with 
health and economic losses related to smoking amounting to $193 billion annually 
(CDC, 2008). Currently, 70% of smokers are interested in quitting (CDC, 2008), but 
many smokers are nicotine dependent (CDC, 2011), making cessation particularly 
difficult. Among individuals who attempt to quit without treatment, only 4-7% are 
abstinent within one year, while cessation rates for combined counseling and 
pharmacotherapy range between 22-32.5% (Fiore et al., 2008). Cessation rates vary 
dramatically for individuals with psychological co-morbidities like depression 
(Niaura et al., 2001) and substance use disorders (Prochaska, Delucchi, & Hall, 2004) 
and are often lower than that observed in the general population. 
Smokers with depressive episodes or elevated depressive symptoms are less 
likely to quit smoking (Lasser et al., 2000), are more likely to relapse (Kinnunen, 
Doherty, Militello, & Garvey, 1996; Niaura et al., 2001; Piper et al., 2010), have 
higher rates of nicotine dependence (Anda et al., 1990), and are more likely to 




Covey, Stetner, & Rivelli, 2001; Killen, Fortmann, Schatzberg, Hayward, & Varady, 
2003; Pomerleau, Marks, & Pomerleau, 2000) than individuals without depressive 
symptomatology. Even low-level depressive symptoms significantly reduce cessation 
rates (Berlin & Covey, 2006; Niaura et al., 2001; Swan, Ward, & Jack, 1996). 
Specific depressive symptoms like anhedonia (lack of/inability to experience 
pleasure) and low positive affect (PA) increase withdrawal symptoms and reduce the 
likelihood of continued abstinence, even when accounting for nicotine dependence, 
current depressive symptoms, and a history of depression (Leventhal, Ramsey, 
Brown, LaChance, & Kahler, 2008).  
A critical behavior to consider among smokers with elevated depressive 
symptoms is substance abuse; 75-95% of individuals in substance use treatment 
smoke cigarettes (Budney et al., 1993; DiFranza & Guerrera, 1990; Kalman et al., 
1998; 2005; Stark & Campbell, 1993) and depression and substance use disorders 
often co-occur (Cerdá, Sagdeo, & Galea, 2008; Grant et al., 2004; Kessler et al., 
2005). Further, 25-61% of individuals in substance use treatment have experienced a 
depressive episode in their lifetime (Chen et al., 2011; Huang et al., 2006; Kessler et 
al., 2003; Regier, et al, 1990).  
In terms of smoking, substance users are more likely than individuals in the 
general population to be nicotine dependent and to have difficulties when attempting 
to quit smoking (Fagerstrom & Aubin, 2009; Ginsburg et al. 1995; Hays et al., 1999; 
Novy, Hughes, & Callas, 2001; Prochaska et al., 2004). Moreover, smoking, not drug 
or alcohol use, is the largest contributor to mortality among substance users (Hurt el 




rate of those who smoked cigarettes was four times higher than the rate among those 
who did not smoke (Hser, McCarthy, & Anglin, 1994). Additionally, tobacco and 
substances have synergistic effects estimated to be up to 50 times higher than the 
effects of either individually, particularly when examining rates of specific types of 
cancers (Bien & Burge, 1990; Pelucchi, Gallus, & Garavello 2007; Zheng et al., 
2004). 
Taken together, the available research suggests that individuals with 
depressive symptoms and substance use disorders represent an important population 
to target in smoking cessation programs because of their combined mood and 
substance-related vulnerabilities. Importantly, individuals with these types of 
vulnerabilities are motivated to quit smoking, with 40-80% of individuals in 
substance use treatment reporting a desire to quit (Clarke et al., 2001; Richter et al., 
2001). Despite the clear negative economic and health-related consequences of 
smoking among individuals with substance use disorders (SUDs) and depressive 
symptoms, few smoking treatments to date have been developed that specifically 
target individuals within these populations. Moreover, the majority of treatment 
research studies exclude these individuals. A thorough search of the literature did not 
uncover a single study specifically focusing on individuals in substance use treatment 
with elevated depressive symptoms who wished to quit smoking.  
Recent work by Okoli and colleagues (2011) demonstrated that individuals 
with substance use disorders and mental illness show enhanced benefits when 
enrolled in more than eight weeks of cessation treatment. Further, there have been a 




disorders and mental health diagnoses. Unfortunately, existing treatments have 
generally shown minimal benefits within these samples. As such, the need for 
smoking cessation treatments targeting individuals with complex diagnostic profiles 
is apparent. Below, a review of smoking cessation treatments that are currently 
available, as well as the extent to which these treatments adequately address the 
issues of substance use and comorbid depressive symptoms, is undertaken. Then, a 
discussion of novel treatment strategies for targeting these combined vulnerabilities is 
introduced. Finally, a plan for testing a novel behavioral activation-enhanced smoking 
cessation treatment is proposed. 
Standard Cessation Techniques Used with Individuals with Co-occurring Disorders  
 The guidelines for treating tobacco use and dependence (Fiore et al., 2008) 
recommend a variety of strategies to aid individuals in their smoking cessation 
attempts. Based on a review of the literature, Fiore and colleagues conclude that a 
combination of cognitive-behavioral and pharmacological treatments provides the 
greatest benefits. These recommended treatments, as well as some novel treatment 
strategies for specific populations, are reviewed below. 
Pharmacological techniques. Nicotine Replacement Therapy (NRT; 
transdermal patches, gum, nasal sprays, inhalers, lozenges) is one of the primary tools 
used for smoking cessation because it helps reduce physiological withdrawal 
symptoms associated with abstinence. The patch has been shown to outperform 
placebo across 17 studies included in a meta-analysis and abstinence rates of 
individuals receiving the patch have been twice that of individuals receiving placebo 




demonstrated to be the most effective form of NRT because it provides a constant 
dose of nicotine, is convenient and easy to use, and reliably reduces withdrawal 
symptoms (Hughes, 1993). 
Among smokers with depressive symptoms or SUDs, however, the benefits of 
NRT may be less robust. Some researchers have not found NRT to benefit depressed 
smokers (Hall et al., 1996), while others have demonstrated attenuated cessation rates 
within depressed samples using the patch as compared to non-depressed samples 
using the patch (Kinnunen, Doherty, Militello, & Garvey, 1996; Kinnunen, 
Korhonen, & Garvey, 2008). Among individuals with alcohol use disorders (AUDs), 
similarly mixed patterns of results have been found. Leeman and colleagues (2007) 
reviewed six articles that used NRT among smokers with a history of AUDs. Four of 
the studies reviewed demonstrated equivalent cessation benefits among smokers with 
and without AUDs, while the remaining two studies showed smokers with AUDs to 
benefit less than their counterparts without AUDs. A meta-analysis examining 
smoking cessation among substance users demonstrated improved cessation outcomes 
when NRT was provided; however, cessation rates were still low, even among 
individuals who received concomitant therapy (Prochaska et al., 2004). Therefore, 
although NRT exerts some benefits among depressed smokers and smokers with 
SUDs, it is clear that other treatments must be utilized in conjunction with NRT to 
achieve higher rates of abstinence among this sub-population of smokers. 
Bupropion has consistently been shown to benefit smoking cessation attempts; 
across 221 studies included in a review article, individuals who received bupropion 




hypothesized to exert its benefits by blocking the reuptake of dopamine and 
norepinephrine, thereby alleviating symptoms of withdrawal during smoking 
cessation (George & O’Malley, 2004). Bupropion does not appear to exert its 
cessation benefits through a reduction of depressive symptoms (Hurt et al., 1997; 
Jorenby et al., 1999) and among highly nicotine dependent individuals, bupropion is 
associated with a strong rebound effect in depressive symptoms when discontinued 
post-cessation (Lerman et al., 2004). Among smokers with a history of an AUD, 
inconsistent results have been found. Specifically, smokers with and without a history 
of an AUD had similar cessation outcomes when using bupropion in three studies, 
while a fourth showed reduced benefits among smokers with an AUD (Leeman, 
Huffman, & O’Malley, 2007). Therefore, it is difficult to determine whether 
bupropion would benefit smoking cessation attempts within substance users with 
elevated depressive symptoms. 
Researchers have also administered bupropion and NRT concurrently to 
determine whether the combination conferred additional benefits. In one study, 
bupropion, or a combination of NRT and bupropion were associated with 
significantly higher rates of continuous abstinence at one-year follow-ups (18.4% and 
22.5%, respectively) compared to placebo and NRT (5.6% and 9.8%, respectively; 
Jorenby et al., 1999), whereas in another study the only treatment to produce 
significantly different abstinence rates at a six month follow-up was a patch + 
nicotine lozenges combination, (compared to other combinations that included 
bupropion; Piper et al., 2009). Importantly, when examining individuals with 




for smoking and NRT) did not increase abstinence rates above and beyond that of the 
standard treatment package (Evins et al., 2008). Similarly, among alcoholics, 
bupropion added to a treatment that included NRT did not confer additional benefits 
(Grant, Kelley, Smith, Agrawal, Meyer, & Romberger, 2007). When examining 
carbon monoxide (CO) levels among substance dependent patients who quit smoking, 
(74% also had a co-occurring Axis I diagnosis) combination treatments that included 
standard psychoeducation, relapse prevention, NRT, and/or bupropion only resulted 
in 7.8% of participants having CO levels less than 9 ppm (parts per million; a quantity 
indicating abstinence) at the final session (Grant et al., 2007). This indicates that 
among our populations of interest- individuals with depressive symptoms and SUDs- 
combined pharmacological treatments might not produce particularly enhanced 
benefits. 
Although pharmacotherapy benefits cessation attempts, the majority of 
individuals need additional strategies to aid in their cessation attempts. Particularly 
among individuals with depressive symptoms or substance use disorders, 
pharmacotherapy does not provide enough support to enable long-term abstinence. 
Therefore, psychological treatments are of particular importance within this 
population. 
Cognitive behavioral techniques. The Guidelines for Treating Tobacco Use 
and Dependence recommend a variety of strategies to aid in cessation, including: self-
monitoring, identifying coping strategies, eliciting social support, making lifestyle 
changes, identifying strategies for relapse prevention, and discussing effective and 




can be categorized as cognitive-behavioral techniques. Although these strategies are 
effective among individuals without comorbid mental health diagnoses, outcomes are 
less favorable when they are applied in samples of  smokers with SUDs or elevated 
depressive symptoms (e.g. Prochaska et al., 2004; Niaura et al., 2001), particularly in 
relation to maintaining abstinence. Smokers with elevated depressive symptoms who 
receive CBT are less likely to maintain abstinence than smokers without elevated 
depressive symptoms (Niaura et al., 2001) and lower rates of abstinence among 
smokers with SUDs who receive CBT have also been reported (Campbell, Wander, 
Stark, & Holbert, 1995; Story & Stark, 1991). 
Important Considerations when Treating Smokers with Comorbid Conditions 
 Although smokers with SUDs and/or mental health diagnoses have difficulties 
maintaining abstinence, it is notable that about 40-80% of smokers in treatment for 
SUDs have expressed interest in smoking cessation (e.g. Clarke, Stein, McGarry, & 
Gogineni, 2001; Richter, Gibson, Ahluwalia, & Schmelzle, 2001). In one study 
examining individuals diagnosed with a psychiatric disorder (e.g. depression) in 
substance use treatment, a smoking cessation attempt was made by 54% of patients 
over the course of six months and 42% were abstinent for at least one day without 
formalized smoking cessation treatment (Unrod, Cook, Myers, & Brown, 2004). 
These studies reveal that individuals with complex diagnostic profiles are able to 
make a short-term cessation attempt without support and suggest that unique 
treatment strategies may help lengthen periods of abstinence.  
Smokers with comorbid diagnoses not only have difficulties maintaining 




sample of patients dually diagnosed with an Axis I disorder and substance 
dependence, only 40% who enrolled in a standard smoking cessation program (which 
included weekly group therapy, NRT, and bupropion, if desired) attended the first 
four treatment sessions. Moreover, only 15% of enrolled patients attended at least 
eight treatment sessions and only 7.8% had CO levels less than 9 ppm at the end of 
treatment (Saxon et al., 2003). A review of smoking cessation programs targeting 
heroin users in methadone maintenance did not reveal significantly higher abstinence 
rates among individuals enrolled in smoking cessation programs compared to those 
who were not enrolled; overall abstinence at 6 month follow-ups ranged from 5-14% 
in the active treatment conditions (Okoli, Khara, Procyshyn, Johnson, Barr, & 
Greaves, 2010). Clearly, researchers working with individuals with multiple mental 
health diagnoses follow the treatment recommendations outlined by Fiore and 
colleagues (2008), but their clients do not evidence cessation rates comparable to 
those seen in less complex populations. Although considerable harm reduction and 
decreased rates of smoking in the short term have been demonstrated, low rates of 
session attendance and abstinence makes apparent the need for treatments that cater to 
this type of population, not only to help retain individuals in treatment, but also to 
provide meaningful benefits in the long-term.  
Alternative Treatment Strategies for Smokers with Elevated Depressive Symptoms 
A number of smoking cessation programs have been developed that aim to 
increase cessation rates above a beyond those found in standard cognitive behavioral 




depressive symptoms specifically focus on reducing depression, while others work 
within standard CBT frameworks, but add complimentary techniques. 
Depressed smokers in a stage-based treatment evidenced more cessation 
attempts than did individuals in a no treatment control group (Hall et al., 2006). The 
stage-based intervention focused on changing clients’ motivation to quit smoking and 
on targeting cessation treatment based on clients’ motivation to quit. The treatment 
was successful, but this may have been less related to the motivational strategies used 
and more related to receiving treatment in general, particularly since previous 
research has demonstrated that individuals with psychiatric disorders are already 
motivated to quit smoking. Moreover, it is also impossible to determine whether the 
focus on clients’ stages of change was relevant, since the study did not include a time-
matched active control condition. 
Cognitive behavioral therapy for mood management has been used among 
individuals who wish to quit smoking and who have had past episodes of major 
depression (Hall et al., 1996; 1998). Overall, the mood management treatment 
produced significantly higher abstinence rates than the standard treatment (ST; Hall, 
Muñoz, & Reus, 1994; Hall et al., 1998), particularly among individuals with 
recurrent depressive episodes (Haas et al., 2004). However, these results were 
confounded by contact time because individuals in the mood management treatment 
received 10 sessions while individuals in ST received five sessions. A later study 
equating for contact time between mood management and ST did not demonstrate 
different cessation outcomes (Hall et al., 1996). In a sample of Spanish speakers, 




outcomes than did self-administered ST (Muñoz, Marín, Posner, & Pérez-Stable, 
1997). Most recently, a treatment program that combined bupropion or NRT and 
cognitive-behavioral techniques for mood management improved abstinence rates 
among German smokers with elevated depressive symptoms and low levels of 
nicotine dependence (Batra et al., 2010), although changes in depressive symptoms 
were not analyzed. Unfortunately, this study also did not provide information on 
cutoff scores for inclusion in the depressive group, making difficult to fully 
understand the clinical profiles of the individuals the treatment benefitted. 
Interestingly, across all of these aforementioned studies, there were no differences 
across treatment conditions in reductions in depressive symptoms, making it difficult 
to determine why the mood management conditions occasionally conferred additional 
cessation benefits.  
Interventions utilizing smoking cessation treatment with a cognitive 
behavioral therapy for depression (CBT-D) component have been tested among 
smokers with past major depressive episodes. When standard smoking cessation 
treatments have been compared to ST supplemented with CBT-D, better cessation 
outcomes have been demonstrated among heavy smokers and among smokers with a 
history of recurrent major depressive disorder (MDD) in ST + CBT-D than in ST 
(Brown et al., 2001). However, smokers with a history of MDD in ST + CBT-D had a 
significantly higher likelihood of developing a major depressive episode than 
individuals in ST during their quit attempts, which clearly is not ideal (Kahler et al., 




treatment, with or without bupropion, it has not conferred additional benefits to 
depressed smokers (Brown et al., 2007).  
The literature has been unable to consistently demonstrate improved smoking 
outcomes when cessation programs have included elements focusing on depressive 
symptoms and negative mood (Hall et al., 1996; Kahler et al, 2002; Brown et al., 
2007). This may suggest that a focus on increasing positive affect, rather than 
combating negative mood, might confer greater benefits. Recently, a promising new 
approach has been utilized that targets depressive symptoms via behavioral activation 
(BA). MacPherson and colleagues (2010) developed a behavioral activation-based 
approach utilizing, standard smoking cessation treatment (ST), behavioral activation 
(BA), and nicotine replacement therapy (NRT). Among community smokers with 
elevated depressive symptoms, this BA-based approach resulted in reductions in 
depressive symptoms and a greater odds of point prevalence abstinence across a six 
month follow-up among individuals receiving BA-enhanced smoking cessation (BA, 
ST, and NRT) compared to individuals receiving standard smoking cessation 
treatment (ST and NRT). Individuals receiving BA-enhanced treatment were 2.26 
times more likely to be abstinent at the end of treatment than individuals in ST and at 
a 26-week follow-up, 16.7% of patients in the BA-enhanced cessation condition were 
abstinent, while 4.2% in the ST condition were abstinent. Further, there was an 
interaction between the treatment conditions and time, in that individuals in the BA-
enhanced treatment had significantly greater decreases in depressive symptoms over 




The successes of this BA-enhanced treatment, not only on cessation outcomes, 
but also in reducing depressive symptoms, suggests it is a promising new approach 
for smokers with unique diagnostic profiles. Since smoking cessation programs 
specifically developed for individuals with SUDs have not demonstrated improved 
long-term cessation outcomes across studies (Prochaska et al., 2004), new 
approaches, like BA are needed. Smokers with depressive symptoms and SUDs are 
among the most difficult to treat and the benefits of this BA-based approach may 
similarly enhance cessation among smokers with SUDs. 
Smoking Cessation among Substance Users 
Individuals with substance use disorders do want to quit smoking and 
previous research has demonstrated that they are able to quit without negatively 
impacting their substance use outcomes; however, long term abstinence is relatively 
rare within this population (Bobo et al., 1998; Burling, Burling, & Latini, 2001; Hurt 
et al., 1994). As mentioned, the meta-analysis of Prochaska and colleagues (2004) did 
not demonstrate significant long-term abstinence effects among substance users in 
smoking cessation treatment (only 3% quit overall); however, individuals enrolled in 
cessation treatments did have significantly higher abstinence rates immediately post-
treatment (12% in the intervention group versus 3% in the comparison group). 
Interestingly, as with non-substance abusing populations, individuals who received 
NRT demonstrated significant increases in abstinence. Further research, with less 
than promising outcomes, focused on smoking cessation among methadone 
maintenance clients and found results similar to the Prochaska meta-analysis; overall 




participated in smoking cessation interventions examined within the review, 
compared to abstinence rates of individuals within control groups in the review 
(Okoli et al., 2010). 
More recently, a multisite study focusing on individuals with SUDs in 
outpatient treatment demonstrated significant increases in abstinence among 
individuals receiving smoking cessation interventions, compared to individuals 
receiving TAU (Reid et al., 2008). Individuals in the smoking cessation program 
received NRT and nine sessions of cognitive behavioral smoking cessation group 
therapy, which included a mood management component. Although only 5-6% of 
individuals were abstinent at the 13 week follow-up visit, this was significantly better 
than the abstinence rates among individuals who did not receive treatment (0%). In 
terms of harm reduction, there were significant decreases in expired CO and 
cigarettes smoked in the active treatment condition, compared to the TAU condition. 
Interestingly, although abstinence rates remained constant among the active treatment 
group at the 26 week follow-up, individuals in the TAU group had increases in 
abstinence, with more than 5% of these individuals abstaining from cigarettes at that 
time. Therefore, at the 26 week follow-up smokers who did or did not participate in 
the cessation program had identical abstinence rates. 
 A smoking cessation study comparing concurrent versus delayed smoking 
cessation treatment for individuals with alcohol use disorders showed abstinence rates 
of 12.4 and 13.7%, respectively at 18 month follow-ups (Joseph, Willenbring, 
Nugent, & Nelson, 2004). Both the concurrent and delayed treatments included NRT 




recommendations of Fiore and colleagues (2000). Individuals who received smoking 
cessation interventions while they were in treatment for their AUDs showed lower 
abstinence rates at six month and one year follow-ups; however the rates of 
abstinence across the two treatment conditions were equivalent at 18 month follow-
ups. Furthermore, individuals in the concurrent treatment group were more likely to 
enroll in cessation programs than individuals in the delayed treatment group (78.5 
versus 64.5%, respectively), which is important. Therefore, treating substance users 
with elevated depressive symptoms while they are in treatment for their SUDs is the 
best course of action as it increases the likelihood that individuals will enroll in 
cessation interventions. 
  Overall, smoking cessation programs aimed at individuals with SUDs have 
produced mixed outcomes. The critical meta-analysis in this area (Prochaska et al., 
2004) demonstrated individuals who enrolled in smoking cessation programs to have 
higher rates of abstinence compared to individuals in control groups post-treatment; 
however significant benefits of enrollment in cessation programs dissipated at long-
term follow-ups. Clearly, it is necessary to try alternative cessation strategies with 
individuals with SUDs, as previous treatments generally have not conferred 
significant benefits within this population. Based on the success of BA-enhanced 
smoking cessation programs among community smokers with elevated depressive 
symptoms (MacPherson et al., 2010) and the success of a BA-enhanced treatment 
among individuals with SUDs and elevated depressive symptoms (Daughters et al., 
2008), it is logical to consider this treatment for smokers with SUDs who have 




and research supporting BA as a treatment for depression is necessary before 
discussing the potential for BA-enhanced therapy among this population.  
Background and Theoretical Underpinnings of Behavioral Activation  
Behavioral Activation (BA) focuses on helping individuals to become 
involved in meaningful, enjoyable activities that resonate with their values across a 
variety of life areas. It is hypothesized that involvement in these activities exposes 
individuals to environments that are more rewarding and enables them to derive 
enjoyment from activities within these environments (Lejuez, Hopko, LePage, 
Hopko, & McNeil, 2001).  
BA is based on the tenets of reinforcement theory, which argues that 
depression results from a loss of positive reinforcement (Ferster, 1973; Lewinsohn, 
1974; Skinner, 1953) and from an increase in punishment for healthy behaviors in 
individuals’ environments (Lewinsohn, Antonuccio, Breckenridge, & Teri, 1984). 
Early research using the Pleasant Events Scale, which monitored the frequency with 
which individuals engaged in pleasant activities and their associated mood, 
demonstrated a significant relationship between frequency of engagement in pleasant 
events and positive mood among depressed, non-depressed psychiatric and non-
depressed controls (Lewinsohn & Graf, 1973; Lewinsohn & Libet, 1972). Depressed 
individuals, in particular, were less likely to engage in pleasant activities; when they 
occasionally did engage in pleasant activities, they were also less likely to experience 
positive mood than controls (Lewinsohn & Graf, 1973). Further, these individuals 
were less likely to seek interpersonal interactions, which may have limited their 




Individuals may be less likely to engage in pleasant events for a variety of 
reasons and the loss of reinforcement they experience can be quantitative (e.g. less 
frequently visiting friends) or qualitative (e.g. certain enjoyable activities have been 
replaced with less enjoyable activities). In this context, researchers have developed 
BA treatments that enable clients to become involved in a greater frequency of 
activities that are pleasant and rewarding (Hopko et al., 2003; Jacobson et al., 1996; 
Lejuez, Hopko, & Hopko, 2001; Lejuez et al., 2001; Martell, Addis, & Jacobson, 
2001). Utilization of these types of treatments have produced significant reductions in 
depressive symptoms, demonstrating benefits comparable to those seen with 
antidepressants and traditional CBT (Dimidjian et al., 2006).  
Comparison of BA to other treatment techniques. Jacobson and colleagues 
(1996) compared BA as a stand-alone treatment to a full CBT treatment package. 
Results of this trial indicated that BA was the critical component across treatments; 
specifically the treatments were equally effective in treating depression at a six-month 
follow-up, indicating that the addition of cognitive components did not significantly 
benefit clients (Gortner, Gollan, Dobson, & Jacobson, 1998; Jacobson et al., 1996). In 
a separate study, Dimidjian and colleagues (2006) found cognitive therapy (CT) to be 
less effective than BA or antidepressants in treating depression among severely 
depressed individuals, in that individuals receiving BA or antidepressants had 
significantly lower Beck Depression Inventory and Hamilton Rating Scale for 
Depression scores than individuals in CT over the course of treatment. In a follow-up 
study assessing the long term effects of these therapies, CT, BA, and medication were 




important treatment strategy for depression (Dobson et al., 2008). A number of 
studies have demonstrated significant decreases in depressive symptoms among 
individuals participating in a BA treatment for depression (Hopko, Lejuez, LePage, 
Hopko, & McNeil, 2003; Lejuez, Hopko, LePage, Hopko, & McNeil, 2001). Finally, 
BA has been established as an evidence-based treatment for depression (Sturmey, 
2009). 
There have recently been three meta-analyses examining the efficacy of 
behavioral activation as a treatment for depression (Cuijpers, van Straten, & 
Warmerdam, 2007; Ekers, Richards, & Gilbody, 2008; Mazzucchelli, Kane, & Rees, 
2009). Cujipers and colleagues (2007) focused on studies using activity scheduling 
(an important component of BA) and demonstrated large pre-post treatment effect 
sizes (.87). Moreover, when BA was compared to CT within these studies, outcomes 
were found to be equivalent. More recently, Ekers and colleagues (2008) compared 
behavioral treatments for depression to supportive counseling and brief 
psychotherapy and concluded that the behavioral treatments were superior to the 
other treatments. Similarly, the Mazzucchelli and colleagues (2009) meta-analysis 
demonstrated an effect size of .78 that favored BA in comparison to control 
conditions and for participants with a major depressive disorder diagnosis, the effect 
size was .74 in favor of BA.  
A more recent study successfully targeted depressive symptoms in substance 
dependent clients using BA (Daughters et al., 2008), under a similar BA protocol 
used in the study conducted by MacPherson and colleagues (2010). Daughters and 




significantly reduced clients’ depressive symptoms, and only 4.5% of clients in the 
BA treatment dropped out of residential substance use treatment compared to 22.7% 
in the treatment as usual condition. Therefore, the BA treatment not only reduced 
depressive symptoms, but also had the potential to improve substance use treatment 
outcomes. A more recent study compared the effects of BA to a contact-time matched 
control condition, supportive counseling (SC), among substance users with elevated 
depressive symptoms (Magidson et al., 2011). Within this study, BA did not result in 
differential changes in depressive symptoms between the two groups; however, 
individuals in the BA treatment were less likely to drop out of substance use 
treatment and more likely to experience enhanced activation than individuals in SC. 
Thus, BA appears to retain individuals in substance use treatment more so than 
supportive counseling, perhaps through increased activation. 
Clearly, BA is a beneficial treatment for individuals with elevated depressive 
symptoms who have a substance use disorder, or who smoke cigarettes. BA may be 
successful because it does not require abstract reasoning skills and because it 
specifically focuses on increasing positive affect, rather than on decreasing negative 
affect. Indeed, Kahler and colleagues (2002) hypothesized that increases in depressive 
symptoms among patients enrolled in their CBT-D condition may have been related 
to participants’ expectation that they would experience depressive symptoms when 
quitting smoking, as learned in the CBT-D intervention. Moreover, recently it has 
been argued that both the heterogeneity of depressive symptoms as well as a focus on 
depression as a broad category has limited the effects of mood-focused smoking 




smoking cessation treatments should target low PA in particular, as a mechanism 
through which to improve cessation outcomes, rather than on decreasing negative 
affect, which has been unsuccessful in the past (e.g. Kahler et al., 2002). Further, they 
argue that behavioral activation may be especially useful for increasing positive affect 
(Leventhal et al., 2008) within these types of samples. 
Behavioral Activation for Drug Abusing Smokers (BA-DAS) 
There is a dearth of research focusing on the unique needs of substance 
abusing smokers with elevated depressive symptoms, who represent an important 
target for smoking cessation interventions. The outcomes of treatments targeting 
depressive symptoms within smokers, depressive symptoms within drug users, and 
smoking among drug users have been mixed, making the continued development and 
examination of treatments for these populations critical. BA may be an ideal 
treatment for substance abusing smokers with elevated depressive symptoms, based 
on its preliminary efficacy among smokers with elevated depressive symptoms 
(MacPherson et al., 2010) and among individuals in residential substance use 
treatment with elevated depressive symptoms (Daughters et al., 2008). BA has been 
shown to be as effective, if not more effective than, CBT; therefore its use in treating 
depressive symptoms in this population may have great utility (Dimidjian et al., 2006; 
Gortner, Gollan, Dobson, & Jacobson, 1998; Jacobson et al., 1996). Moreover, BA is 
unique because of its focus on increasing positive affect, rather than on decreasing 
negative affect, which may be of key importance in this type of population (Leventhal 




As previously mentioned, CBT can be difficult for some clients to 
comprehend; clients with low abstract reasoning skills do not show improvements in 
CBT in comparison to 12-step treatments (Maude-Griffin et al., 1998). Because BA 
relies heavily on changing individuals’ activity patterns, rather than their cognitive 
patterns, it may be easier for individuals with lower level abstract reasoning skills to 
succeed in BA than in CBT. Furthermore, the simplicity of BA means it may be 
easier in the future for drug treatment center staff to implement it, as many staff 
members lack the background necessary to administer complex theory-based 
treatments like CBT (McCoy, Messiah, & Zhao, 2002). Indeed, few drug treatment 
centers actually integrate treatments for mental health diagnoses into their standard 
treatments, (Drake, Mueser, Brunette, & McHugo, 2004), often leaving clients who 
have multiple diagnoses with insufficient care. 
Current Study 
The current study compared a novel integrated behavioral activation smoking 
cessation intervention (BA-DAS) to treatment as usual (TAU) among smokers with 
elevated depressive symptoms in a residential substance use treatment center in 
Washington D.C. Treatment as usual included all of the standard substance abuse 
treatment groups at the center, transdermal nicotine replacement therapy, and the 
National Cancer Institute’s Clearing the Air manual. TAU represented the treatment 
likely to be provided to individuals in residential substance use treatment who wished 
to quit smoking. BA-DAS included key elements of cognitive behavioral smoking 
cessation treatment, NRT, and critical elements of behavioral activation. BADAS was 




treatment conditions, individuals’ self-reported smoking statuses, carbon monoxide 
output, depressive symptoms, positive affect, anhedonia, activation levels, and drug 
use were monitored before, during, and after treatment to determine whether BA-
DAS significantly benefited smokers, as compared to TAU. As an accepted standard 
in smoking cessation research, a number of cessation outcomes were examined, 
including seven-day point-prevalence abstinence, time to relapse (smoking five 
cigarettes per day for three days in a row), and smoking reductions (Hughes et al., 
2003; Shiffman et al., 2006). Multiple outcomes were examined, because different 
outcomes have implications for processes by which treatments work as well as 
specific behavioral targets of intervention (e.g. Shiffman et al., 2006). It was 
hypothesized that participants in BA-DAS would (1) show significantly higher point 
prevalence abstinence rates, lower cigarette consumption, and a longer time to relapse 
(2) evidence significant reductions in depressive symptoms, (3) exhibit significant 
increases in positive affect, and (4) become more active and derive more pleasure 
from being active. All outcomes were assessed over treatment and at two-week and 





Aim 1: To compare smoking outcomes among substance users with elevated 
depressive symptoms as a function of treatment condition. 
A1a: To examine time to relapse as a function of treatment condition. 
Hypothesis 1a: Participants in TAU will more quickly relapse to smoking 
than participants in BADAS. 
A1b: To examine seven day point prevalence abstinence as a function of 
treatment condition. 
Hypothesis 1b: There will be higher abstinence rates among smokers in 
BADAS than among smokers in TAU.  
A1c: To examine reductions in cigarette consumption as a function of treatment 
condition. 
Hypothesis 1c: There will be greater overall reductions in cigarette 
consumption among smokers in BADAS than among smokers in TAU. 
Aim 2. To examine changes in depressive symptoms over time as a function of 
treatment condition.  
Hypothesis 2: Smokers in BADAS will evidence greater reductions in 
depressive symptoms over time than will individuals in TAU. 
Aim 3: To examine changes in activity levels and rewards over time as a function of 
treatment condition. 
Hypothesis 3. Individuals in BADAS will exhibit greater increases in 
activity levels and enjoyment derived from being active over time than 




Exploratory Aim: To examine treatment satisfaction and treatment compliance 









Chapter 2: Method 
 
Participants  
All participants were recruited from a residential substance use treatment 
center in Washington D.C. The majority of participants at the center were low-
income, African Americans who were court-mandated to receive substance use 
treatment (see Table 1). The most common treatment contract length was 30 days, but 
participants could stay at the center for up to 180 days and the center provided 
transition services upon treatment completion (see Table 1). Participants were 
recruited during their first week of residential treatment after complete detoxification, 
which typically occurred in specialized facilities prior to entering the center.  
Treatment at the center included a variety of programs intended to help participants 
develop a substance-free lifestyle, based on Alcoholics Anonymous and Narcotics 
Anonymous techniques as well as on strategies focusing on the development of 
relapse prevention skills. Participants were involved in group therapy, work therapy, 
Bible study, educational programs, literacy education, and anger management 
programs, which lasted from 8am to 9pm Monday-Saturday. Sundays were spent in 
church at the treatment facility. Residents were only permitted to leave the center for 
treatment required activities (e.g. physician visits, to attend court hearings). The 
center regularly drug tested participants and positive drug screens were grounds for 
dismissal. Participants were provided five smoking breaks daily and all participants 




breaks. Participants were allowed to have two packages of cigarettes delivered to the 
treatment center by friends or family members once weekly.  
All individuals at the treatment center received a standard intake assessment 
within their first week of arriving to the treatment center. Those who met preliminary 
inclusion criteria for our study were invited to complete a baseline assessment to 
determine full eligibility. Participants in our study were: (1) between the ages of 18-
65; (2) had a BDI-II score of at least 7 during the intake assessment (in line with 
MacPherson et al., 2010); (3) were motivated to quit smoking (endorsed at least a 5 
on a scale from 1-10 for motivation to quit during the intake assessment), (4) and 
regularly smoked (were smokers who reported smoking at least 5 cigarettes/day and 
having smoked for at least one year during the intake assessment). We excluded 
participants if they (1) endorsed psychotic symptoms (as assessed by the SCID-IV 
during the intake assessment), (2) had limited mental competency and/or the inability 
to give informed consent, (3) reported using tobacco products other than cigarettes 
during the baseline assessment (but not excluding mini cigars, like Black and Milds), 
(4) had physical concerns that prevented them from using the patch (further described 
below), (5) reported using other medications to quit smoking during the baseline 
assessment, (6) were reading below a 5
th
 grade reading level, or (7) reported initiating 
psychotropic medications within the prior three months during the intake assessment. 







Screening and Recruitment 
Graduate students and research assistants supervised by Dr. Lejuez 
administered the SCID-IV (Spitzer, Gibbon, & Williams, 1995) to assess Axis I and 
II disorders as a part of the initial intake procedures for all participants at the 
treatment center. Participants reported basic demographic information, completed the 
Beck Depression Inventory-II (BDI-II; Beck, Steer, & Brown, 1996), and provided 
information about their daily smoking levels and motivation to quit smoking during 
their intake assessments. Based on this initial information, participants who were 
eligible, based on the aforementioned inclusion and exclusion criteria, were invited to 
complete further assessments administered by research assistants to determine 
whether they would be eligible to participate in the current study. These participants 
completed a brief medical history questionnaire focusing on contraindications for 
transdermal nicotine patch use (i.e., cardiovascular, neurological, renal, 
immunological problems, pregnancy/ breast feeding, significant medical/systemic 
illnesses). Women received additional questions regarding their plans to become 
pregnant within the following six months and their use of birth control. The study 
nurse followed up with participants who endorsed contraindications for patch use 
during this initial screener. As multiple research studies are conducted by our staff at 
this residential treatment center, participants who met inclusion criteria for more than 
one study were allocated to studies based on the study need. Of the 353 participants 
we screened, there were 48 who met our inclusion and exclusion criteria; 31 were 
invited to participate in our study and 17 were recruited to participate in other studies 




Treatment Group Assignment and Basic Treatment Components 
Participants were assigned to TAU or BADAS within four sequential cohorts. 
This type of assignment schedule minimized potential bleeding effects of the BA-
DAS treatment into the TAU condition, as many participants often overlapped at the 
treatment center while they were quitting smoking. Participants 1-7 and 15-19 
recruited into the study were assigned to the TAU condition, while participants 8-14 
and 20-24 were assigned to the BA-DAS treatment condition.  
Treatment for BADAS participants consisted of five 60-90 minutes sessions 
conducted over 2 ½ weeks, with the quit day scheduled to occur on the third session. 
Treatment included transdermal nicotine replacement therapy (NRT), standard 
cognitive behavioral smoking cessation treatment components, and behavioral 
activation. Treatment for TAU participants included transdermal NRT and NCI’s 
Clearing the Air manual. By design, participants in TAU were assigned a quit day 
that occurred five to nine days after their baseline assessment session to most closely 
approximate the number of days between the baseline assessment session and session 
three for participants in the BADAS treatment condition.  
Transdermal nicotine replacement therapy. All participants in BADAS and 
TAU received the Nicoderm CQ, 24-hour transdermal nicotine patch, with the initial 
dose calibrated to match the participants’ average number of cigarettes smoked. For 
example, a participant who generally smoked 14 cigarettes per day started on the 14-
mg patch, while a participant who generally smoked a pack-a-day (20 cigarettes) 
began on the 21-mg patch. In line with manufacturer’s recommendations, participants 




weeks of the 14-mg patch and two weeks of the 7-mg patch, while participants who 
started on the 14-mg patch received the 14-mg dose for 6 weeks, followed by two 
weeks of the 7-mg patch. Participants were provided with the safety information 
instructions provided with the patch. Prior to the third session (or four days after the 
baseline assessment for participants in TAU), participants were educated on the use 
of the patch and possible side effects were discussed. The importance of wearing the 
patch for the full two months was emphasized. Participants who continued smoking 
while receiving the patch, or who lapsed while using the patch, were instructed to 
discontinue use of the patch if their smoking level reached four cigarettes per day for 
four days. Participants who discontinued use of the patch because of a smoking lapse 
were encouraged to set a new quit day. 
 Cognitive behavioral techniques for smoking cessation. Participants in 
BADAS received components of standard smoking cessation techniques based on the 
most recent guidelines provided by the U.S. Department of Health and Human 
Services, Treating Tobacco Use and Dependence (Fiore et al., 2008). In the first two 
sessions, participants discussed previous quit attempts, the benefits of quitting, high 
risk situations, coping skills, and enlisting social support. During the third session, 
participants discussed the first day of their quit attempt, coping strategies they had 
used/intended to use, and high risk situations they thought they might encounter. The 
final two sessions focused on their quit experiences, patch use, withdrawal symptoms, 
strategies for avoiding smoking, and the perceived benefits of quitting. The treatment 
included a condensed form of these topics, as to allow time for the BA components of 




30 minute sessions; Fiore et al., 2008) this condensed ST format was able to cover 
necessary areas, while providing time for the BA components of therapy.  
Behavioral activation for drug abusing smokers (BADAS). The BA-DAS 
treatment manual was developed using strategies tested among community smokers 
with elevated depressive symptoms (MacPherson et al., 2010) and strategies used 
among individuals with substance dependence and elevated depressive symptoms 
(Daughters et al., 2008). The BA-DAS manual was developed in an iterative fashion, 
with participant and therapist feedback that occurred during pilot sessions informing 
different iterations of the treatment manual. The BADAS manual used in this study 
included simplified behavioral monitoring forms, re-wording in several sections to 
ease comprehension, and better integration of standard smoking cessation techniques 
with BA techniques.  
Behavioral activation strategies focused on helping participants form 
rewarding smoke-free lifestyles. Behavioral activation components (Lejuez et al., 
2001; 2011) in BA-DAS included 1) daily completion of an activity and smoking log; 
2) identification of important life areas (i.e. Relationships, Career/Education, Free 
Time, and Wellness) and values (things that are valued by an individual within these 
specific life areas); 3) selection of activities that enable participants to live their lives 
according to their values within these specific life areas; 4) formulation of a schedule 
with participants to determine when activities will be performed; and 5) assessment of 
completion of activities and modification of selected activities when necessary. 
Participants were encouraged to engage in these treatment components so they would 




Therapists regularly ensured participants understood the connection between 
involvement in important/enjoyable activities, mood, and smoking behaviors. 
Session 1: During the first session, therapists explained the components and 
rationale of the BA-DAS treatment. After discussing the standard smoking cessation 
treatment strategies (outlined above), therapists introduced the Daily Activity and 
Smoking Form, and instructed participants to record their activities (including the 
importance and enjoyment associated with these activities), mood, and cigarette 
consumption each day for the remainder of treatment. Then, the therapist discussed 
participants’ normal daily activities, with a consideration of the importance and 
enjoyment of these activities. Therapists encouraged participants to reflect on how 
their involvement in important/enjoyable activities affected their mood and smoking 
behaviors. In this session, the therapist also elicited participants’ opinions on the 
benefits of quitting smoking and information about their past quit attempts as a part of 
the standard CBT-based smoking cessation component. 
Session 2: Participants reflected on the enjoyment and importance of activities 
they completed since the last session and were encouraged to note patterns between 
the importance/enjoyment of their activities, their mood, and their patterns of 
cigarette smoking. Participants discussed any difficulties encountered with daily 
activity monitoring. Therapists then introduced the concepts of life areas and 
important values within these areas. Participants identified their values within their 
life areas (i.e., Relationships, Career/Education, Free Time, and Wellness). They then 
brainstormed activities related to their values using the Life Areas, Values, and 




following week, participants selected activities from their LAVA form and scheduled 
them within specific time slots. The therapist encouraged participants to select 
important and enjoyable activities congruent with their values. Therapists suggested 
participants choose the easiest activities to complete first, increasing the likelihood of 
activity completion. Therapists emphasized that being active in enjoyable and 
important activities would better enable participants to remain abstinent from 
cigarettes. Standard treatment components were discussed at the end of the treatment 
session and included an introduction to the patch and information about high risk 
situations and eliciting social support for quitting. Participants were provided their 
first NRT patch by the therapist and were instructed to apply it the night prior to, or 
the morning of, their quit attempt. 
Session 3: Participants’ Daily Activity and Smoking Forms were reviewed. 
Difficulties participants had in completing scheduled activities were discussed. Then, 
participants scheduled activities from their LAVA form for the following week on 
their Daily Activities and Smoking Form. Participants were encouraged to continue 
engaging in activities they had already selected, as well as to add additional 
enjoyable/important activities from their LAVA form. Participants had the 
opportunity to discuss concerns about the patch and quitting smoking. Standard 
smoking cessation treatment components were further discussed, in particular the 
abstinence violation effect and high risk situations.  
Sessions 4 and 5: During the fourth and fifth sessions, participants continued 
adding more activities to their Daily Activity and Smoking Form and discussed 




also created contracts to be used with individuals within, as well as outside of, the 
treatment center. Participants selected activities from their LAVA forms for which 
they desired social support. They then selected individuals whom they believed could 
help them complete these activities. Standard smoking cessation techniques were 
integrated throughout these sessions. 
Therapists 
The therapists for this study included graduate students and senior research 
assistants who were extensively trained and supervised in BA and CBT-based 
smoking cessation techniques. These therapists shadowed experienced therapists 
conducting smoking cessation treatment sessions during the piloting stages of 
treatment development. They received supervision sessions with Dr. MacPherson 
throughout the duration of treatment administration. The therapist manual specifically 
outlined the components and steps of treatment for each session and treatment 
supervisors reviewed these areas as necessary during supervision. All therapy 
sessions were audiotaped and reviewed to ensure compliance with the treatment 
manual. 
Measures 
Several assessments were used to examine a variety of important variables, 
including: (1) basic demographics (age, gender, ethnicity, marital status, income 
level, employment status, and education level), (2) smoking information: smoking 
history, current cigarette consumption, type of cigarettes smoked (regular, menthol, 
black and milds, etc.), nicotine dependence, and smoking outcomes (Time Line 




Dependence, Smoking: Self-Efficacy/Temptation Short Form, salivary cotinine, 
carbon monoxide analysis of breath samples), (3) motivation to quit smoking, (4) 
depressive symptoms and mood (Beck Depression Inventory, the Profile Of Mood 
States, Snaith-Hamilton Pleasure Scale, Environmental Reward Observation Scale), 
(5) activity levels (BADS), and (6) treatment adherence (homework completion 
checklist completed by the therapist). Participants enrolled in BA-DAS and TAU 
completed all assessments at the five time points. 
Timeline follow back (TLFB; Sobell, Maisto, & Sobell, 1979; Sobell & 
Sobell, 1979; 1992; 1996). The TLFB is a reliable and valid self-report measure for 
examining individuals’ use of cigarettes and drugs over time. It is the standard tool 
for retrospectively examining individuals’ smoking rates, has demonstrated high test-
retest reliability when analyzing drug use, and correlates with urinalysis results 
(Brown et al., 1998; Fals-Stewart, O’Farrell, & Freitas, 2000). During our baseline 
interview, participants provided information about the number of cigarettes they 
smoked daily for each of the prior 90 days. They also reported substances used during 
each of the prior 90 days, including number of alcoholic beverages consumed. 
Participants completed the TLFB at the third session, at the fifth session, and at a two 
week post-treatment follow-up session. During these additional assessment sessions, 
they reported on their cigarette, alcohol, and substance use since the prior assessment 
session. Participants’ reports on the TLFB were compared to biochemical 
assessments of abstinence (carbon monoxide; CO output) and when there were 




Time Line Follow Back data were used to determine all of our primary 
smoking-related outcomes. Data collected on the TLFB were used to calculate 7-day 
point-prevalence abstinence rates, which were defined as self-reported abstinence 
(verified with CO) for blocks of seven days assessed at four points post-quit (Hughes 
et al., 2003). Time 1 abstinence was defined as: not smoking from quit day through 
day 6 post-quit; time 2 abstinence was defined as: not smoking from day 7 post-quit 
through day 13 post-quit; time 3 abstinence was defined as: not smoking from day 14 
post quit through day 20 post-quit; time 4 abstinence was defined as: not smoking 
from day 21 post-quit through day 27 post-quit. If participants smoked during a time 
period, they were coded as not abstinent. Time Line Follow Back data were also used 
to examine smoking reductions across the aforementioned four blocks of time. Thus, 
the total number of cigarettes smoked during time 1 (days 0-6 post quit), time 2 (days 
7-13 post-quit), time 3 (days 14-20 post-quit), and time 4 (days 21-27 post-quit) were 
examined. Time Line Follow back data were used to examine time to relapse, which 
was defined as the number of days from quit date until the participant smoked five 
cigarettes per day for three days in a row post-quit (Shiffman et al., 2006).  
Biochemical verification. Expired carbon monoxide (8ppm cutoff) via a 
Vitalograph Breathco carbon monoxide monitor for self-reported abstinence was used 
as a biochemical verification of self-reported abstinence. In cases of discrepancy 
where self-report indicated abstinence and biochemical measurement indicated 
smoking, the participant was coded as smoking. 
Diagnoses, depressive symptoms, and mood states. Axis I and II diagnoses 




which was administered to participants by trained doctoral level students and senior 
research assistants within the first week of admission to the treatment center. The 
Beck Depression Inventory-II (BDI-II; Beck, Brown, & Steer, 1996), which is a well-
validated measure assessing the existence and severity of depressive symptoms, was 
used to determine whether participants met the clinical cutoff to be included in the 
study. The BDI-II was administered at each assessment time point. The Profile of 
Mood States (POMS; McNair, Lorr, & Droppleman, 1971) has demonstrated 
psychometric properties and was used in the current study to examine week-to-week 
changes in mood.  
Activity level and enjoyment. Participants’ activity levels were assessed 
throughout treatment using a variety of tools. The Environmental Reward 
Observation Scale (EROS; Armento & Hopko, 2007) was used to gather general 
information about participants’ engagement in and enjoyment of activities. The 
EROS is a 10 item measure with strong divergent and convergent reliability that was 
administered at each assessment point. The Behavioral Activation for Depression 
Scale (BADS) is a scale with demonstrated reliability and validity, which was used to 
assess participants’ behavioral activation throughout treatment (Kanter, Rusch, 
Busch, & Sedivy, 2009). The four subscales (Activation, Avoidance/Rumination, 
Work/School Impairment, and Social Impairment) have adequate to strong internal 
consistency (α = .75 - .92), as does the Total score (α = .87). The Total score, as well 
as the Activation scores, were used in the current study. 
Treatment satisfaction and compliance. A paper-based survey was created to 




Participants rated the frequency with which they completed their daily activity and 
smoking forms, how helpful they found the various components of treatment, the 
clarity of the presentation of the materials, and their compliance with activity 
scheduling. They also described the components of treatment they found to be 
helpful/not helpful. The six participants recruited into the first BADAS cohort 
completed these treatment rating forms after each treatment session. This survey was 
not completed by the six participants in the second BADAS cohort for administrative 
reasons. The therapists also rated participants’ treatment compliance after each 
treatment session (see Appendix 2). Therapists recorded participants’ homework 
completion, the number of activities scheduled and completed, the number of life 
areas targeted by the activities, and clients’ participation during the treatment 
sessions. Therapists completed this adherence form for eight of the 12 participants in 
BADAS. 
Medical history. Participants were screened for nicotine replacement therapy, 
via the patch, using a medical screener questionnaire. If participants endorsed specific 
symptoms that contraindicated patch use, they were referred to the study nurse for 
further screening.  
Data Analysis  
 Prior to data entry, the completed questionnaires and interview sheets were 
reviewed and checked for completeness or obvious errors. Data were double entered 
into SPSS (versions 16-18 over the course of the study) so potential inconsistencies or 




 Missing data. There were missing data points due to participants dropping out 
of treatment or due to difficulties contacting participants for the one-month follow-up 
assessment (see Figure 1). On the quit day assessment, 100% of participants in 
BADAS completed the assessment, whereas 91.7% of participants in TAU completed 
the assessment. On the assessment occurring after the final treatment session, 100% 
of participants in BADAS completed the assessment, while 83.3% of participants in 
TAU completed the assessment. Finally, 75% of participants in BADAS completed 
the one-month follow-up assessment, whereas 41.7% of participants in TAU 
completed the one-month follow-up assessment. To determine whether there were 
differential follow-up rates in BADAS and TAU, a chi-square analysis was conducted 
examining the relationship between treatment group and participating in the follow-
up assessment. The relationship was not significant (p > .05). Participants who did 
not complete the follow-up assessment had the greatest amount of missing data for 
the TLFB, since the one-month follow-up generally collected smoking data for the 
prior 2-3 weeks.  
Administrator error resulted in missing data for some measures. In TAU, there 
were six missing data points for CO data for participants who self-reported abstinence 
on the TLFB, while in BADAS, there was one missing CO data point for a participant 
who self-reported abstinence. These data were missing because of equipment 
malfunction, or because the assessment administrator failed to collect CO data. There 
were also five participants with missing data for education and income; imputation 
was not used because of the small sample size, the limited number of demographic 




There were occasional missing data points due to non-responses. When 
greater than 80% of data points were present for the self-report measures (e.g. BDI, 
BADS), totals scores were computed, with imputation for missing data points 
(average scores, based on other responses on the measure, were imputed). Of the 
assessments completed, imputation was only required in 3.7% of cases. There were 
no assessments where less than 80% of data points were complete.   
Continuous independent variables were centered before conducting any 
analyses. Data collected on covariates were examined for non-normality and were log 
transformed to achieve normality. After transformation, the skew and kurtosis for the 
BDI-II was -.49 and -.21, respectively; for the BADS was -.50 and .24, respectively; 
and for the POMS Depression subscale was .40 and -1.11, respectively, indicating 
that the transformation reduced skewness and kurtosis. 
Aim 1 analyses. Participants’ time to relapse was computed using survival 
analysis, with treatment condition as the grouping factor (Niaura et al., 2001; 
Shiffman et al., 2006), which estimated the risk of relapse by examining time to 
relapse in relation to treatment group assignment. The hazard ratio (HR) was 
computed using Cox regression with treatment condition, BDI score, gender, and 
baseline cigarettes per days as covariates; all were entered simultaneously. The HR 
indicates the ratio of risk in BADAS as compared to TAU, where a higher HR 
indicates that individuals in BADAS are less likely to relapse than individuals in 
TAU. An examination of the survival distribution within the Kaplan-Meier survival 
analysis, using the Wilcoxon test was conducted, which indicates differences in group 




Repeated measures analyses were conducted using generalized estimating 
equations (GEE), which is an extension of the generalized linear model that assumes 
correlated observations, in this case within subjects over time, of independent and 
dependent variables (Hanley et al., 2003), to examine point prevalence abstinence 
rates. GEE was used because it can accommodate missing time points, can handle 
repeated measures within subject data, and because a working group formed by the 
Society for Research on Nicotine and Tobacco recommended using GEE when 
examining smoking outcomes (Hall et al., 2001). Participants who dropped out of 
treatment or who could not be contacted were coded as being not abstinent, per 
accepted standards in the smoking field. GEE was used to examine differences in the 
odds of being abstinent (measured as 7-day point prevalence abstinence) between 
individuals in BA-DAS and TAU in seven day increments for the 28 days post-quit. 
Time Line Follow Back (TLFB) data were used to determine 7-day point prevalence 
abstinence at each assessment point. Individuals were considered to be abstinent at a 
particular time point if they had not smoked in the prior 7 days. Here, expired CO was 
used as a biological indicator of abstinence to confirm smoking reported on the 
TLFB, with levels lower than 8 ppm coded as abstinent. Treatment type (BA-DAS 
and TAU) was used as the independent between groups variable in this analysis. 
Based on the literature (Cinciripini et al., 2003; MacPherson et al., 2010), depressive 
symptoms (BDI-II), average daily cigarette consumption prior to quitting, gender, and 
the linear effect of time were examined as covariates. For this analysis because the 
outcome measure was binary, we used a logit link function with a binomial 




GEE also was used to examine differences in cigarette consumption between 
BADAS and TAU. Daily cigarette consumption data obtained via the TLFB were 
combined into seven day blocks to determine average daily cigarette consumption 
over the four weeks of treatment and follow-ups. All available data were included in 
these analyses. Treatment type was the independent between groups variable and as 
above, the BDI-II, baseline cigarette consumption, gender, and the linear effect of 
time were examined as covariates. For this analysis, we used an identity link function, 
a normal distribution, and an independent correlation matrix. 
Aim 2 analyses. GEE was used to examine changes in depressive symptoms 
(BDI-II; POMS Depression subscale) over the course of treatment and follow-ups. 
The treatment type (BADAS versus TAU) was used as the independent, between 
groups variable, and gender and the linear effect of time were included as covariates. 
For GEE analyses examining changes in BDI and POMS Depression scores, we used 
an identity link function, a normal distribution, and an independent correlation matrix.  
Aim 3 analyses. GEE was used to examine changes in activity levels and 
environmental reward over treatment. Activity levels were examined with BADS 
scores as the dependent variable and treatment condition as the independent between 
groups variable. Rewards derived from participation in activities were analyzed with 
EROS scores as the dependent variable and treatment condition as the independent 





Chapter 3: Results 
 
Aim 1 Analyses 
Time to relapse. In comparing rates of early relapse (i.e., smoking five 
cigarettes per day for three days in a row) within TAU, 58.3% relapsed within the 
first seven days post-treatment, while within BADAS, 16.7% relapsed within the first 
seven days post-treatment (χ
2
(1) = 4.44, p = .035; see Figure 2). Those in TAU 
demonstrated a mean survival time of 14.75 days until relapse, which was less than 
those in BADAS, who demonstrated a mean survival time of 23.00 days until relapse 
(χ
2
(1) = 3.59, p = .058). At the final assessment point during the one-month follow-
up, 66.7% of participants in BADAS had not relapsed to smoking, as compared to 
41.7% of participants in TAU (p = .219). Using a cox regression analysis, the 
significance of the full model, including treatment condition, baseline BDI, gender, 
and baseline smoking was shown to be not significant χ
2
(4) = 3.95, p = .410. Within 
this model, treatment condition approached significance for predicting time to relapse 
(χ
2
(1) = 3.37, p = .071, HR = 4.0, see Figure 2). 
Point-prevalence abstinence. Seven-day point prevalence abstinence rates 
were examined using GEE.  None of the included covariates examined (BDI, gender, 
baseline smoking levels) were significantly related to point-prevalence abstinence 
rates (Table 2). Among participants in TAU, 33.4% were abstinent at the first 
assessment point (days 0-6), 25.0% were abstinent at the second assessment point 
(days 7-13), 16.7% were abstinent at the third assessment point (days 14-20), and 




BADAS, 8.3% were abstinent at the first assessment point, 25.0% were abstinent at 
the second assessment point, 25.0% were abstinent at the third assessment point, and 
16.7% were abstinent at the fourth assessment point. Seven day point prevalence 
abstinence rates did not differ as a function of treatment condition (β = 1.06, SE = 
1.05, p = .313), as a function of time (β = 0.02, SE = 0.36, p = .947), or as an 
interaction between the two (β = -0.26, SE = 0.50, p = .606; see Table 2 and Figure 
3). Thus, participants’ abstinence rates did not increase over time. 
Cigarette smoking rates. Among participants in TAU, the average weekly 
cigarette consumption during the first week post quit was 12.00 cigarettes (SD = 
14.45), during the second week post-quit was 8.82 (SD = 12.48), during the third 
week was 10.00 (SD = 13.11), and during the fourth week was 11.97 (SD = 12.98). 
Among participants in BADAS, the average weekly cigarette consumption during the 
first week post-quit was 5.81 cigarettes (SD = 6.25), during the second week post-quit 
was 10.08 (SD = 21.36), during the third week post-quit was 11.13 (SD = 22.54), and 
during the fourth week post-quit was 12.88 (SD = 22.13). Participants’ cigarette 
consumption did not differ as a function of treatment condition (β = 0.08, SE = 1.01 p 
= .937), time (β = 0.36, SE = 0.29 p = .215) or the interaction between treatment 
condition and time (β = 0.23, SE = 0.37 p = .533; see Figure 4 and Table 3). None of 
the included covariates examined (BDI, gender, baseline smoking levels) were 
significantly related to smoking rates post-quit (Table 3).  
Aim 2 Analyses 
Beck depression inventory. For TAU, the BDI scores at baseline, quit day, the 




(SD = 8.60), 5.70 (SD = 2.21), and 2.80 (SD = 2.39), respectively. For BADAS, the 
BDI scores at baseline, quit day, the final treatment session, and the one month 
follow-ups were: 13.55 (SD = 9.02), 12.58 (SD = 6.59), 9.36 (SD = 5.94), and 6.67 
(SD = 8.47), respectively. Within the GEE analysis, there was a significant effect of 
time; participants’ BDI scores decreased significantly over treatment and follow-ups 
(B = -0.15, SE = 0.03, p < .001; see Figure 5). However, within the GEE analyses 
BDI scores did not differ as a function of treatment condition (B = 0.17, SE = 0.12, p 
= .160), gender (B = 0.01, SE = 0.15, p = .943), or the interaction between treatment 
condition and time (B = 0.03, SE = 0.06, p = .542; see Table 4). 
The profile of mood states. For TAU, the POMS Depression scores at 
baseline, quit day, the final treatment session, and the one month follow-ups were: 
5.75 (SD = 5.69), 4.33 (SD = 6.00), 4.70 (SD = 7.73), and 1.40 (SD = 1.94), 
respectively. For BADAS, the POMS Depression scores at baseline, quit day, the 
final treatment session, and the one month follow-ups were: 8.55 (SD = 9.26), 6.92 
(SD = 6.70), 3.64 (SD = 5.09), and 2.00 (SD = 1.87). The POMS depression scale 
score did not differ as a function of treatment condition (B = 0.89, SE = 1.92, p = 
.643), the interaction between treatment condition and time (B = -1.19, SE = 1.11, p = 
.284), or by gender (B = 0.92, SE = 2.05, p = .653; see Table 4). There was a 
significant effect of time, in that POMS depression scores decreased over time (B = -
0.82, SE = 0.30, p = .007; see Figure 6). 
Aim 3 Analyses. 
The environmental reward observation scale. For TAU, the EROS scores at 




25.00 (SD = 4.79), 26.33 (SD = 5.65), 27.60 (SD = 4.27) and 29.78 (SD = 3.98), 
respectively. For BADAS, the EROS scores at baseline, quit day, the final treatment 
session, and the one month follow-ups were: 23.73 (SD = 4.27), 25.00 (SD = 5.44), 
28.27 (SD = 6.41), and 30.00 (SD = 5.64), respectively. EROS scores did not differ as 
a function treatment condition (B = -0.01, SE = 0.03, p = .748), or the interaction 
between treatment condition and time (B = 0.01, SE = 0.02, p = .475; see Table 5). 
There was a significant increase in environmental reward across treatment and 
follow-ups (B = 0.03, SE = 0.01, p < .001; see Figure 7). 
The behavioral activation for depression scale. The BADS Total score and 
BADS Activation score did not differ as a function of treatment condition, time, the 
interaction between treatment condition and time, or as a function of any of the 
included covariates (see Table 5).  
Treatment satisfaction and compliance. Participants reported on their 
treatment compliance and satisfaction at each treatment session. Participants rated 
how useful the specific skills learned were in terms of helping them quit smoking. On 
a categorical scale where a 1 indicated “not at all useful” and a 5 indicated “extremely 
useful”, the average score participants rated the BADAS treatment to be was 4. 
Participants rated the extent to which skills learned in BADAS helped them to 
increase their positive mood; on a categorical scale where 1 indicated “not at all” and 
5 indicated “a great deal” the average score of BADAS participants was 4.4. Finally, 
participants rated the extent to which skills learned in the BADAS program helped 




indicated “a great deal”. All participants reported that the program helped them a 
great deal; the average score reported across participants was five.  
On the qualitative portion of the survey, participants were given the 
opportunity to describe the elements of treatment they found to be helpful, and the 
elements of treatment they would change. In describing elements they found to be 
helpful, participants wrote comments like “My worker- she was encouraging and 
helpful”; “The young lady that’s helping me”; “Helping me find activities”; “Being 
able to discuss stressful situations that may have caused me to smoke”; “Making a list 
to see how I view my emotions and what I want to do about each one”; and “Using 
the patches”. In describing elements of the treatment that they would change, 
participants wrote, “None”; “Keep up the good work”; “Keep doing what you’re 
doing”; “Less meetings and bringing snacks or gum to fight the urges to smoke”; 
“Keep things as they are”; and “None”. 
The number of scheduled activities participants completed between each 
session was divided by the number of days between each session to determine the 
average number of activities completed daily by participants in BADAS. Overall, 
participants completed one scheduled activity every two days (or .594 activities 
daily). Six participants created one contract, while two participants created two 
contracts. On average, participants schedule activities targeted 2.44 life areas out of 





Chapter 4: Discussion 
This is the first study to our knowledge to compare a behavioral activation-
enhanced smoking cessation treatment, to a basic smoking cessation treatment, in a 
residential substance use treatment center for participants with elevated depressive 
symptoms. This small-scale trial provides important information relevant for future 
larger-scale studies on the effects of BA-enhanced smoking cessation treatments. 
Smoking cessation outcomes will first be discussed below. Then, outcomes for mood 
and activations levels will be reviewed. Finally limitations of the study and future 
directions will be noted. 
Smoking Outcomes 
Participants in BADAS were significantly less likely to relapse to smoking 
within the first seven days post-quit. Moreover, their time to relapse approached 
significance, in that participants in BADAS on average relapsed on the 23
rd
 day post-
quit, as compared to participants in TAU, who on average relapsed on the 15
th
 day 
post-quit. This suggests that the BADAS treatment benefitted participants during the 
time in which they were most vulnerable to relapse, that is within the first couple of 
weeks post-quit (Brown, et al., 2001 ; Cook, Gerkovich, O’Connell, & Potocky, 1995 
; Doherty, Kinnunen, Militello, & Garvey, 1995 ; Garvey, Bliss, Hitchcock, Heinold, 
& Rosner, 1992). Our findings suggest that participants in BADAS may require 
additional follow-up treatment sessions in order to avoid relapsing over time, 
particularly during the third and fourth weeks post-quit. During this time, participants 
with a 30-day treatment contract at the Center completed substance use treatment; the 




Follow-up therapy during this time would allow BADAS participants to revisit their 
values and the activities available to them in their new living situations. This support 
would likely increase activation, mood, and abstinence rates. 
Although participants in BADAS were significantly less likely to relapse 
during their first week post-quit, they did not demonstrate significant group 
differences in terms of point prevalence abstinence rates or smoking reductions. 
There are a number of factors that may help to explain these findings. Abstinence and 
cigarette consumption metrics focus on different processes than measures of relapse. 
Relapse rates focus on whether a pattern consistent with returning to smoking has 
been established, whereas abstinence and cigarette consumption rates focus on 
whether, and how much, participants are smoking daily. In addition, there are a 
number of broader systemic factors that help explain the pattern of findings for 
measures of abstinence and cigarette consumption. These include our small sample 
size—which limited our power to detect differences between the two treatment 
conditions, the established difficulties associated with quitting smoking more 
generally within this population (e.g. Baca & Yahne , 2009; Prochaska et al., 2004), 
and broader environmental barriers that made it difficult for participants to 
successfully implement treatment techniques (Burling et al., 1997; Orleans & 
Hutchinson, 1993. These will be more fully discussed below. 
First, substance users in general experience particular difficulties with quitting 
smoking. Even among substance users who receive NRT and concomitant therapy, 
cessation rates are still quite low (Prochaska et al., 2004). A review by Baca and 




rates ranging from 4.7% at a six-month follow-up to 23.4% at a one-week follow-up. 
Similarly, Okoli and colleagues (2010) found overall abstinence rates of substance 
users at six month follow-ups ranging from 5-14%. In a sample of patients dually 
diagnosed with an Axis I disorder and substance dependence, only 7.8% had CO 
levels less than 9 ppm at the end of an eight-session treatment (Saxon et al., 2003). 
The above findings mirror the abstinence rates observed within our sample. Overall, 
low cessation rates appear to be the norm, rather than the exception, among substance 
users.  
Second, the low overall cessation rates among substance users make it 
particularly difficult to detect differential cessation outcomes across treatment 
conditions, as beneficial treatments may often have smaller effect sizes, which would 
necessitate large samples to detect significant effects. Following this, there are a 
number of studies that have not shown differential treatment outcomes across 
treatment conditions for smokers with substance use disorders. It is unclear whether 
the lack of significant findings across studies is due to small effect sizes, or whether 
the treatments compared actually do not differentially affect smoking outcomes. A 
study of substance users in an active smoking cessation treatment condition, 
compared to substance users in a TAU condition, demonstrated equivalent cessation 
outcomes at a 26-week follow-up (Reid et al., 2008). Similarly, a review of studies of 
former heroin users receiving methadone maintenance compared active smoking 
cessation treatments to control conditions, but did not find significantly different 
outcomes between the active treatments and control conditions (Okoli et al., 2010). 




differences in smoking cessation rates across different conditions within this type of 
population.  
Third, there are a number of environmental factors that can help to explain 
why substance users in particular may have difficulties quitting smoking. Burling and 
colleagues (1997) discuss environmental barriers to quitting among substance users, 
including higher rates of smoking among peers and family members of substance 
users than among non-users; the majority of substance users live with smokers 
(Orleans & Hutchinson, 1993) and the majority of substance users’ peers in substance 
use treatment smoke (Prochaska et al., 2004). This makes this group particularly 
vulnerable, as they are regularly exposed to smoking cues that may compromise their 
ability to maintain abstinence. Moreover, substance use treatment providers often do 
not support cessation attempts (e.g. Prochaska et al., 2004). One example within the 
treatment center where our study was conducted concerned a policy implemented 
midway through the study that required participants to go outside during smoking 
breaks, even if they wished to stay inside to avoid smoking cues. Engaging in 
alternative activities, such as reading books or writing letters during breaks, often was 
challenging because of rules proscribing participants from carrying books or loose 
paper with them during the day. The difficulties for some participants in BADAS to 
select alternative rewarding activities during their cessation attempt may help explain 
their low point prevalence abstinence rates. Anecdotally, many participants reported 
that they were dissatisfied with the types of activities they were able to schedule 




Third, previous research has demonstrated that smokers with depression, as 
compared to nonpsychiatric smokers, choose smoking as a preferred activity more 
often and ascribe more benefits to smoking (Spring, Pingitore, & McChargue, 2003). 
Moreover, smokers with depression also find cigarettes to be more appealing than 
alternative rewards and believe that the benefits of smoking outweigh the costs, 
whereas nonpsychiatric smokers perceive the pros and cons to be equivalent (Spring 
et al., 2003). Thus, our participants may already have had difficulties finding other 
activities to be rewarding because of their elevated depressive symptoms, which were 
then compounded by their difficulties in scheduling potentially rewarding activities 
during their quit attempts. It will be important in future work to determine what 
treatment dose is necessary to counteract these effects, that is, how many activities 
participants need to schedule in order to improve their mood and thus decrease some 
of the reward potential of cigarettes. It will also be interesting to examine whether the 
duration of a rewarding activity (five minutes versus 30 minutes) is of particular 
importance, or whether the overall enjoyment and importance associated with an 
activity is what is most critical. Finally, it is also necessary to examine whether 
follow-up treatment sessions would decrease participants’ likelihood of relapse, as it 
would encourage continued engagement in alternative rewarding activities post-
treatment, which is where relapse rates increased for participants in BADAS. Overall, 
there are challenges with implementing this type of treatment within our setting; 
however, there are a number of factors that can be examined in future work that will 





Mood and Activation 
Previous research has demonstrated that early relapse is associated with low 
positive mood and elevated depressive symptoms (e.g. Holt, Litt, & Cooney, 2012; 
Niaura et al., 2001; Zvolensky, Stewart, Vujanovic, Gavric, & Steeves, 2009). 
Further, depression has been shown to predict early relapse (smoking at one week 
post-quit), but not late relapse (smoking at six months post-quit) among individuals 
attempting to quit smoking (Japuntich et al., 2007). Thus, it was important to us to 
target depressive symptoms in BADAS. Similar to the findings of a number of prior 
smoking cessation studies, the addition of a treatment component aimed at improving 
participants mood during cessation did not differentially improve participants’ mood, 
as compared to a treatment condition that did not target participants’ mood (e.g. Hall 
et al., 1994, 1996, 1998; Kahler et al., 2001; Muñoz et al, 1997; Patten et al., 1998). 
Although there were no significant group differences in POMS depression or BDI 
scores, there were significant decreases in both scores across both treatment 
conditions over time. There are a number of factors that might help to explain why 
BADAS and TAU did not differentially impact participants’ mood that will be 
discussed.  
First, although participants reported on the treatment satisfaction and 
compliance surveys that BADAS helped them to become more active and helped to 
improve their mood, it is possible that they did not get a large enough treatment dose 
to impact their mood. Prior BA research has not determined the necessary BA 
treatment dose necessary to increase participants’ moods. On average, participants in 




improvements in participants’ mood would have been observed if they had completed 
more activities throughout treatment. Additionally, it is possible that participants in 
BADAS had difficulties implementing BA treatment techniques while at the 
residential substance use treatment center because of the restrictive nature of the 
center. As participants had group activities scheduled daily from 9am-9pm, and as 
they were unable to leave the treatment center, it was difficult for many participants 
to schedule activities they saw to be important and enjoyable while at the center. 
Finally, many participants attempted to solely schedule their activities during their 
smoking breaks, rather than scheduling activities throughout the day while at the 
treatment center. Although therapists emphasized the importance of scheduling 
activities throughout the day, participants often wanted to schedule their activities to 
coincide with smoke breaks, so that they would have an alternative enjoyable activity 
to do during those times. In the future, it will be important to more strongly 
encourage participants to schedule activities during alternative times as well as during 
smoke breaks. Because of somewhat low level of activity scheduling in BADAS, it is 
possible that other factors may have had a larger impact on participants’ moods 
during treatment. 
It is possible that participants in our sample generally became more active and 
had enhanced moods over the course of drug treatment, as many were incarcerated or 
homeless prior to entering treatment. Further, participants’ reductions in depressive 
symptoms may have been more strongly related to their continued abstinence from 
drugs and alcohol during substance use treatment (e.g. Liappas, Paparrigopoulos, 




participants within this drug treatment center meet diagnostic criteria for substance 
dependence (e.g. Chen et al., 2011) it is likely that a large percentage were not 
engaged in alternative rewarding activities prior to entering treatment. Thus, the 
decreases in negative moods over the course of treatment may have been tied to 
participants’ mood changes over treatment in both conditions because of the profound 
impact of entering residential treatment and becoming abstinent from drugs. These 
changes in environmental context, and adjustment to the new context, may have had a 
larger impact on participants’ activation and mood scores that their smoking cessation 
treatment condition (e.g. Kosten et al., 2003; Rounsaville, Kosten, & Kleber, 1986). 
This suggests that it might be important to recruit participants after they have adjusted 
to the treatment center (during their third week of treatment, rather than during their 
first week of treatment) and to follow them for longer periods of time post-treatment 
in order to see significant benefits of the BADAS treatment on mood and activation 
outcomes. It is possible that our short follow-up period did not allow us to observe 
changes in mood that may have occurred post-treatment, which is similar to the 
findings of Magidson and colleagues (2011) and Daughters and colleagues (2008). 
Their research suggested that there might be halo effects for measures of mood in 
TAU that dissipate over longer term follow ups. In general, it is possible that our lack 
of significant findings for mood and activation may have been more related to our 
lack of power due to our very small sample size, or to the short follow-up period 
within the current study, rather than to an actual lack of differences. 
In general, participants in our TAU condition demonstrated unexpected 




condition in Daughters and colleagues (2008) study of BA for depression for 
substance users, participants in our TAU condition did unexpectedly well, 
considering that our participants merely received NRT. For example, Daughters and 
colleagues (2008) TAU group demonstrated an increase on the EROS from about 24 
at baseline to 25 post-treatment, as compared to TAU in the current study which 
demonstrated an increase in the EROS from about 25 at baseline to 30 at the final 
assessment. The increase in EROS scores in our TAU group was actually larger than 
the EROS increases in Daughters and colleagues (2008) BA group (about 23 at the 
baseline and 26 post-treatment). Similarly, participants in our TAU condition 
demonstrated a seven point decrease in their average BDI score from baseline to the 
final assessment session, as compared to the five point decrease in Daughters and 
colleagues (2008) TAU and the 10 point decrease in their BA group. When 
comparing BDI scores in our sample to the BDI scores of participants in MacPherson 
and colleagues’ (2010) study of BA for smokers with elevated depressive symptoms 
(BATS), a similar pattern of findings emerges. For example, MacPherson and 
colleagues (2010) standard treatment participants experienced a four point decrease in 
their BDI scores from baseline to their one-week post-quit assessment, while 
participants in BATS experienced a six point decrease during that same time period, 
which is comparable to the decrease in our TAU condition (seven point decrease).  It 
is unclear why our TAU condition experienced these increases in environmental 
reward and decreases in depressive symptoms during their quit attempt. It will be 




control groups within future smoking cessation studies in this population, or whether 
this pattern is unique to our particular sample.  
Treatment Satisfaction 
Participants in BADAS were generally very satisfied with the smoking 
cessation treatment they received; noting that the techniques taught, the therapist with 
whom they worked, and the NRT received, were helpful. Participant treatment 
satisfaction is important for a number of reasons. It has been suggested that 
individuals’ treatment preferences are critical when considering treatment through 
collaborative models of care (Katz, 2001). Additionally, patient satisfaction predicts 
treatment outcomes and health-related behavioral decisions (Albrecht & Hoogstraten, 
1998; Brody, Miller, Lerman, Smith, Caputo, 1989). Following this, it may be that     
participants in BADAS were generally compliant with the BA portion of treatment 
because they were satisfied with the treatment they were receiving. Participants 
completed most of their homework assignments, which is critical in treatments 
targeting elevated depressive symptoms (Addis & Jacobson, 2000). However, it is 
possible that the effects of treatment may have been diluted by the low number of 
activities scheduled by participants and the narrowness of the life areas targeted. It is 
possible that participants within our study may have placed too much of a focus on 
scheduling activities during smoke breaks at the treatment center, rather than 
scheduling pleasant activities throughout the day. This may have narrowed 







There are a number of important limitations to consider when interpreting 
these findings. First, the small sample size resulted in insufficient power to detect 
anything but large group differences in smoking and mood outcomes. The sample 
size also impacted our ability to examine whether covariates like sex, age, or baseline 
depressive symptoms affected smoking or mood outcomes. Second, the control 
condition included in the current study was not contact-time controlled, which limits 
conclusions about the effects of BADAS. Third, CO data were missing for six 
assessment points in TAU and one assessment point in BADAS, which prevented us 
from biochemically verifying participants’ abstinence rates at every assessment point. 
These missing data were due to administrator errors, particularly those that occurred 
in the first cohort of TAU participants that were recruited. This is a common problem 
in smoking cessation studies, particularly in cases where follow-up assessments are 
conducted by phone. Fourth, we lost contact with several participants after they were 
discharged from the substance use treatment center, which introduces error into our 
analyses examining smoking outcomes and participants’ mood at the one-month 
follow-up assessment. Fifth, despite random assignment of participants to BADAS 
and TAU, there were more women in BADAS than in TAU and there were some 
differences in terms of educational backgrounds and incomes between the two 
groups; these factors were all controlled for in all analyses. Sixth, the sample was 
homogenous in terms of race; future research is needed to determine whether these 
findings apply to participants who are not African American. Seventh, it is possible 




those with elevated BDI scores; perhaps excluding participants with low BDI scores 
narrowed our potential recruitment pool. Finally, the EROS has been recently 
supplanted by the RPI (Carvalho et al., 2011), which is a stronger measure of 
environmental reward.  
Future Directions 
 Future work examining the efficacy of BA-enhanced smoking cessation 
treatments among substance users in residential treatment would benefit from a 
number of changes. A larger sample size would increase power and would enable the 
detection of small, but meaningful effects. As noted by Prochaska and colleagues 
(2004), even small effects are important in smoking cessation work because of their 
large impacts on morbidity and mortality. A larger sample size would also enable us 
to determine whether this treatment differentially impacted smokers with particularly 
elevated depressive symptoms, or whether it differentially impacted depressive 
symptoms over time. Related to this, a longer follow-up period would enable us to 
determine whether the effects of either treatment condition persisted for a longer 
period of time. Similarly, it would be beneficial to have follow-up treatment sessions 
so that therapists could help participants in BADAS to continue scheduling activities 
after leaving the treatment center. In order to determine whether BADAS 
differentially impacted both smoking cessation and mood, it would be necessary to 
compare it to a contact-time controlled cessation condition, which will be important 
in future work. Although the current study did not observe differences in cessation 
rates and mood, future work is necessary in this area, as there are relatively few 




effects may have been due to the small sample size and poor follow-up rates. Finally, 
one area that may be of particular importance is staff buy-in, as a number of 
participants reported struggling with the constraints imposed by the treatment center 
in utilizing strategies discussed in our cessation treatment sessions. 
 In conclusion, although a number of the outcomes examined in this study 
were not significantly different, there are a number of factors that argue for the 
potential benefits of BADAS as a smoking cessation treatment for substance users 
with elevated depressive symptoms. First, participants in BADAS endorsed high 
levels of treatment satisfaction. In general, they did not suggest any modifications to 
the treatment. Second, participants were willing to schedule and engage in activities, 
even though doing so was often difficult at the treatment center. On average, they 
completed a scheduled activity every other day throughout treatment. Third, 
participants in BADAS were significantly less likely to relapse during their first week 
post-quit, which is the time in which they are most vulnerable to relapse. Overall, 
further examination of this treatment is necessary, as it could prove to be of particular 














Comparisons on Baseline Demographic, Smoking History, and Affective Variables 
across Treatment Conditions. One way ANOVAs were used for continuous variables, 
chi-square analyses were used for categorical variables. Not all percentages add to 
100 because of missing data.     
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Demographics        
    % Female   16.7   41.7 .19 
    % African American   100   100 N/A 
    % Court-mandated   72.7   36.4 .10 
    Average Age 40.17 7.72  39.18 10.25  .80 
    Average treatment length    
(in days)  
34.16 17.61  34.50 17.53  .96 
Education        
    Middle school graduate   -   8.3 .028 
    Some high school   33.3   8.3  
    High school graduate/GED   41.7   16.7  
    Some college   -   41.7  
Average household income        
    $0-9,999   33.3   25 .015 
    $10,000-19,999   -   16.7  
    $20,000-29,999   41.7   -  
    $30,000+   -   33.3  
Smoking History Variables        
    Number of year smoking 20.42 7.73  18.27 10.95  .59 
    FTND 5.42 2.47  5.18 2.36  .82 
    Average cigarettes per day 12.47 6.77  13.85 13.28  .75 
Baseline Affective Variables        
    BDI-II  11.00 7.83  13.55 9.02  .48 
    POMS depression 5.75 5.66  8.55 9.26  .39 








Generalized Estimating Equations Predicting Seven Day Point Prevalence 
Abstinence. 
 
 OR 95% CI p 
Main Effects    
    Treatment Condition 1.92 [0.24, 15.56] .540 
    Time 1.03 [0.55, 1.93] .921 
    BDI 1.10 [0.99, 1.22] .091 
    Gender 0.19 [0.03, 1.43] .107 
    Baseline Smoking 1.04 [0.93, 1.16] .524 
Interaction    





























 OR 95% CI p 
Main Effects    
    Time 1.43 [0.81, 2.54] .215 
    Treatment Condition 1.08 [0.15, 7.76] .937 
    Gender .216 [0.24, 1.92] .169 
    BDI 3.41 [0.64, 1.06] .151 
    Baseline Smoking 0.99 [0.93, 1.05] .640 
Interaction    





Generalized Estimating Equations Predicting Depressive Symptoms Scores 
 
  
OR 95% CI p 
BDI Score Predictors    
    Treatment Condition 1.21 [0.96, 1.53] .102 
    Time .807 [0.76, 0.86] .001 
    Treatment x Time 1.073 [0.95, 1.21] .242 
    Gender .983 [0.74, 1.30] .906 
POMS Depression Predictors    
    Treatment Condition 2.44 [0.06, 10.56] .643 
    Time .187 [0.06, 0.55] .002 
    Treatment x Time .306 [0.04, 2.67] .284 










Table 5.  
 





OR 95% CI p 
EROS Score Predictors    
    Treatment Condition .990 [0.93, 1.05] .748 
    Time 1.03 [1.02, 1.05] .001 
    Treatment x Time 1.01 [0.98, 1.04] .475 
    Gender 1.00 [0.92, 1.09] .999 
BADS Total Score Predictors    
    Treatment Condition 1.04 [0.97, 1.11] .319 
    Time 1.04 [1.02, 1.06] .001 
    Treatment x Time 1.02 [0.98, 1.07] .326 











Figure 1.  
 
Recruitment and Retention Consort Diagram. Participants were screened based on a 
number of criteria outlined in the Method section. 
 
* N’s here do not sum to 305 because some participants had multiple characteristics 
that excluded them from the current study. Only individuals who smoked at least one 





Figure 2.  
 
Time to Relapse. Relapse is defined as smoking five cigarettes per day for three days 








Conservative Seven Day Point-Prevalence Abstinence. Data from all participants are 
included in this graph. Each time point represents a seven-day time period. Subjects 
who did not smoke during a seven day time period are coded as abstinent. Missing 







Figure 4.  
Cigarette Consumption over Treatment and Follow-ups. The number of cigarettes 
participants smoked post-quit are graphed as a function of time. Each time point 
represents the average weekly cigarette consumption during the seven-day block, by 





















BDI Scores as a Function of Treatment Condition and Time. Assessments occurred at 
baseline, quit day, final treatment session day (the equivalent for TAU), and at a two 
week follow-up. Each time point represents the average score of all data collected at 












POMS Depression Scores as a Function of Treatment Condition and Time. 
Assessments occurred at baseline, quit day, final treatment session day (the 
equivalent for TAU), and at a two week follow-up. Each time point represents the 








Figure 7.  
Environmental Rewards as a Function of Treatment Condition and Time. 
Assessments occurred at baseline, quit day, final treatment session day (the 
equivalent for TAU), and at a two week follow-up. Each time point represents the 



































UMD LET’S Quit Program Survey 1 
 
Instructions: Please answer each of the following questions as it relates to your 
experience in our quit smoking program.  
 
 
1.  I was able to complete the Daily Activity and Smoking Forms.  
  
 
1  2  3  4  5 
   No, never    Some of the time  Yes, all of the time 
 
2. When I could not complete the Daily Activity and Smoking Forms it was 
because (circle all that apply):  
a) I forgot 
b) It was too much work 
c) I did not want to 
d) It was difficult to understand what to do 
e) I didn’t have time to do it 
f) Other:  
___________________________________________________________ 
 
3. I found rating the “importance” and “enjoyment” of my activities to be 
helpful.  
 
1  2  3  4  5 
No, not at all helpful  Somewhat helpful  Yes, very helpful 
 




4. It was helpful to track the number of cigarettes I smoked each day.   
 
1  2  3  4  5 
 No, not at all helpful  Somewhat helpful  Yes, very helpful 
 










5. I found the presentation in my manual of “values” and “life areas” to be clear.  
 
1  2  3  4  5 
No, not at all clear  Somewhat clear   Yes, very clear 
 







6. I found the presentation in my manual of “activities” to be clear.   
 
1  2  3  4  5 
 No, not at all clear  Somewhat clear   Yes, very clear 
 













8. What suggestions do you have for any changes for the LET’S Quit Program 


















UMD LET’S Quit Program Survey 2 
 
Instructions: Please answer each of the following questions as it relates to your 
experience in our quit smoking program.  
 
 
1.  I was able to complete the Daily Activity and Smoking Forms.  
  
 
1  2  3  4  5 
   No, never    Some of the time  Yes, all of the time 
 
2. When I could not complete the Daily Activity and Smoking Forms it was 
because (circle all that apply):  
a) I forgot 
b) It was too much work 
c) I did not want to 
d) It was difficult to understand what to do 
e) I didn’t have time to do it 
f) Other:  
___________________________________________________________ 
 
3. I found the presentation in my manual of “values” and “life areas” to be clear.  
 
1  2  3  4  5 
No, not at all clear  Somewhat clear   Yes, very clear 
 






4. I was able to schedule a variety of activities for the upcoming week.  
 
1  2  3  4  5 
No, not able               Somewhat able                      Yes, very 
able 
 
If you responded “1” or “2”, what about it was difficult and prevented your from 















8. What suggestions do you have for any changes for the LET’S Quit Program 











UMD LET’S Quit Program Survey 3 
 
Instructions: Please answer each of the following questions as it relates to your 
experience in our quit smoking program.  
 
 
1.  I was able to complete the Daily Activity and Smoking Forms.  
  
 
1  2  3  4  5 
   No, never    Some of the time  Yes, all of the time 
 
2. When I could not complete the Daily Activity and Smoking Forms it was 
because (circle all that apply):  
a) I forgot 
b) It was too much work 
c) I did not want to 
d) It was difficult to understand what to do 
e) I didn’t have time to do it 
f) Other:  
___________________________________________________________ 
 
3. I found the presentation in my manual of “values” and “life areas” to be clear.  
 
1  2  3  4  5 
No, not at all clear  Somewhat clear   Yes, very clear 
 






4. I was able to schedule a variety of activities for the upcoming week.  
 
1  2  3  4  5 
No, not able               Somewhat able                      Yes, very 
able 
 
If you responded “1” or “2”, what about it was difficult and prevented you  from 








5. It was difficult for me to complete my scheduled activities   
 
1  2  3  4  5 
 It was not difficult       It was somewhat difficult            It was very difficult 
 






6. I found the presentation in my manual of “Contracts” to be clear.   
 
1  2  3  4  5 
 No, not at all clear  Somewhat clear   Yes, very clear 
 













8. What suggestions do you have for any changes for the LET’S Quit Program 



















UMD LET’S Quit Program Survey 4 
 
Instructions: Please answer these questions about your experience in our quit 
smoking program.  
 
1.  I was able to complete the Daily Activity and Smoking Forms.  
  
 
1  2  3  4  5 
   No, never    Some of the time  Yes, all of the time 
 
2. When I could not complete the Daily Activity and Smoking Forms it was 
because (circle all that apply):  
g) I forgot 
h) It was too much work 
i) I did not want to 
j) It was difficult to understand what to do 
k) I didn’t have time to do it 
l) Other:  
___________________________________________________________ 
 
3. I found the presentation in my manual of “values” and “life areas” to be clear.  
 
1  2  3  4  5 
No, not at all clear  Somewhat clear   Yes, very clear 
 






4. I was able to schedule a variety of activities for the upcoming week.  
 
1  2  3  4  5 
No, not able               Somewhat able                      Yes, very 
able 
 
If you responded “1” or “2”, what about it was difficult and prevented your from 








5. It was difficult for me to complete my scheduled activities from last session
  
 
1  2  3  4  5 
 It was not difficult       It was somewhat difficult            It was very difficult 
 




6. I created a Contract with someone at Harbor Light  Yes        No 
 










8. What suggestions do you have for any changes for the LET’S Quit Program 






How useful were the specific skills learned in the program in helping you quit 
smoking? 
1. Not at all useful 
2.  Slightly useful 
3.  Moderately useful 
4. Very useful 
5. Extremely useful 
 
To what extent did the skills you learned in the program help you increase 
positive moods? 
1. Not at all  
2. A slight amount 
3. A moderate amount 
4. A good deal  
5. A great deal 
 
To what extent did you experience negative moods while quitting smoking? 




2.  A slight amount 
3. A moderate amount 
4. A good deal  
5. A great deal 
 
How much did negative moods jeopardize your success at quitting smoking and 
staying quit? 
1. Not at all  
2. A slight amount 
3. A moderate amount 
4.  A good deal  
5. A great deal 
 
To what extent did the skills you learned in the program help you be more active 
while at Harbor Light? 
1. Not at all  
2. A slight amount 
3. A moderate amount 
4. A good deal  






Homework Completion Form-BA-DAS 
Name:  
Date of first session:  
Date of last session:  
Total # of Sessions Attended:  
Total # of Sessions Missed:  
 
Session 1, Date:  
 
Please rate the client’s participation on a scale from 1 to 5:  
 
Session 2, Date: 
 
Please rate the client’s participation on a scale from 1 to 5:  
 
Total # of Days Possible for Recording   
Total # of Days Completed for Recording Daily Activities  
Total # of Days Completed for Recording Enjoyment/Importance Ratings  
Total # of Days Cigarettes Smoked Recorded  
Total # of Days Mood Recorded  
 
Session 3, Date:  
 
Please rate the client’s participation on a scale from 1 to 5:  
 
Total # of Days Possible for Recording   
Total # of Days Completed for Recording Daily Activities  
Total # of Days Completed for Recording Enjoyment/Importance Ratings  
Total # of Days Cigarettes Smoked Recorded  
Total # of Days Mood Recorded  
 
Session 4, Date:  
 
Please rate the client’s participation on a scale from 1 to 5:  
 
Total # of Days Possible for Recording  
Total # of Days Completed for Recording Daily Activities  
Total # of Added Activities  
Total # of Added Activities Completed  
Total # of Life Areas Targeted in Activities   
 
Session 5, Date:  
 
Please rate the client’s participation on a scale from 1 to 5:  
 
Total # of Days Possible for Recording  
Total # of Days Completed for Recording Daily Activities  
Total # of Added Activities  
Total # of Added Activities Completed  
Total # of Life Areas Targeted in Activities   
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